Biogen beats estimates with earnings and revenues

22 July 2020
biogen_large

Shares in US biotech Biogen (Nasdaq: BIIB) were up by 1.5% following 90 minutes of trading on Wednesday after the company presented its second quarter financial results.

Second quarter total revenues were $3.68 billion, a 2% increase versus the second quarter of 2019 and ahead of analyst expectations of $3.43 billion.

Important to this was Tecfidera (dimethyl fumarate), Biogen’s best-selling treatment, which generated sales of $1.18 billion in the quarter, ahead of Wall Street estimates of $1.11 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology